Therefore, the inhibition of BCL10 may represent a potentially novel therapeutic method for different CB-SMOC-dependent disease conditions, ranging from ABC-DLBCL and other aggressive cancers to inflammatory diseases such as psoriasis. The gene discussed is BCL10; the disease is psoriasis.